$15.19 Billion Worldwide Neurodegenerative Disorder Therapeutics Industry to 2030 – Identify Growth Segments for Investment – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Neurodegenerative Disorder Therapeutics Global Market Report 2021: COVID-19 Growth and Change to 2030” report has been added to ResearchAndMarkets.com’s offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global neurodegenerative disorder therapeutics market.

The global neurodegenerative disorder therapeutics market is expected to grow from $14.08 billion in 2020 to $15.19 billion in 2021 at a compound annual growth rate (CAGR) of 7.9%.

The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $20.15 billion in 2025 at a CAGR of 7%.

Companies Mentioned

• Biogen
• Pfizer
• Novartis
• Sanofi
• Teva Pharmaceutical
• UCB
• Hoffmann- La Roche Ltd
• ACADIA Pharmaceuticals Inc.
• Lundeck A/S
• Boehringer Ingeiheim International GmbH
• Merck Serono
• Orion Pharma Ltd
• Mitsubishi Tanabe Pharma America
• Allergan
• GlaxoSmith Kline PLC
• AbbVie
• Eli lilly
• Celgene
• Neuro- Hitech Inc.
• Bayer Schering Pharma AG
• Amarin Corporation
• AstraZeneca
• Alector
• Yumanity Therapeutics
• Yangtze River Pharmaceutical Group
• Chongqing Zein Pharmaceutical
• Eisai

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

The neurodegenerative disorder therapeutics market consists of sales of neurodegenerative disorder therapeutics products and related services for neurodegenerative disorders. Neurodegenerative disorder is a range of incurable conditions that primarily affect the neurons of human brain and results in progressive degeneration or death of nerve cells. The neurodegenerative disorder therapeutics deals with the manufacturing and development of drugs and treatment that stops or slows down the neurodegenerative processes of diseases such as Parkinson’s, Alzheimer’s, Huntington’s and other neurodegenerative disorders.

The neurodegenerative disorder therapeutics market covered in this report is segmented by indication type into Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington disease, other indications. It is also segmented by drug type into n- methyl- d- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors, others and by distribution into hospital pharmacy, retail pharmacy, online pharmacy.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

High rates of failure in clinical trials and research and development (R&D) have always been a major challenge in the neurodegenerative disorder therapeutics market. Companies are continuously investing in R&D to develop treatments for neurodegenerative diseases but currently very few treatments are approved for neurodegenerative disorders. According to a study in 2019, there are officially 112 new molecular entities in Alzheimer’s disease (AD) clinical trials, although there are 3558 in cancer trials.

For instance, 12 of the 42 (28 per cent) drugs certified by the US Food and Drug Administration (FDA) were oncology therapies, this compares with 0% of AD drugs in production. This failure entitled Alzheimer’s disease drugs to the highest rates of failure at 99.6% when compared to any other disease, including cancer, which has a failure rate at 81%.

Increased prevalence of neurodegenerative among the global population contributes to the growth of neurodegenerative disorder therapeutics market. The increase in the number of geriatric population, attributes to the increased prevalence of neurodegenerative disorders.

According to World Population Prospects, the number of people above 60 years of age increased to 2.1 billion in 2050 and it is expected that people aged over 80 years will triple to 425 million in 2050. According to the Alzheimer’s Association, around 5.8 million Americans are suffering with Alzheimer’s disease and this number is projected to rise to around 14 million by 2050. The increased prevalence of neurodegenerative diseases among the ageing population increases the demand for neurodegenerative disorder therapeutics thereby driving the market.

Manufacturers of neurodegenerative disorder therapeutics are undergoing various strategic partnerships with government and non- government organizations to discover and develop therapeutics for a range of neurodegenerative diseases. The companies in the neurodegenerative disorder therapeutics market are also increasing their collaboration with other players in the market in order to increase their capabilities for research and development activities in order to develop new and more effective therapeutic solutions to treat neurodegenerative disorders.

For more information about this report visit https://www.researchandmarkets.com/r/3ob2sg

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900